J M Bliss - JoVE Visualize

Showing results (61-70 of 70) with videos related to

Pageof 7

Sort By:

You have reached the last page of results.This site can display upto 70 results.

Breast Cancer Research and Treatment|November 28, 2017

Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIESM C U Cheang, J M Bliss, G Viale, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996

Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer GroupR C Coombes, J M Bliss, J Wils, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2004

A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trialI E Smith, R P A'Hern, G A Coombes, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 24, 2015

Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†V Speirs, G Viale, K Mousa, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2005

Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCGD Nitti, J Wils, J Guimaraes Dos Santos, et al.

Breast Cancer Research and Treatment|November 15, 2014

NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancerC Palmieri, S Cleator, L S Kilburn, et al.

The Lancet. Oncology|March 22, 2008

The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial, S M Bentzen, R K Agrawal, et al.

Lancet (London, England)|March 22, 2008

The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial, S M Bentzen, R K Agrawal, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 24, 2022

Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancerN C Turner, C Swift, B Jenkins, et al.

Lancet (London, England)|February 20, 2007

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialR C Coombes, L S Kilburn, C F Snowdon, et al.

Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:

Pageof 7

You have reached the last page of results.This site can display upto 70 results.

Breast Cancer Research and Treatment|November 28, 2017

Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIESM C U Cheang, J M Bliss, G Viale, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996

Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer GroupR C Coombes, J M Bliss, J Wils, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2004

A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trialI E Smith, R P A'Hern, G A Coombes, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 24, 2015

Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†V Speirs, G Viale, K Mousa, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2005

Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCGD Nitti, J Wils, J Guimaraes Dos Santos, et al.

Breast Cancer Research and Treatment|November 15, 2014

NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancerC Palmieri, S Cleator, L S Kilburn, et al.

The Lancet. Oncology|March 22, 2008

The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial, S M Bentzen, R K Agrawal, et al.

Lancet (London, England)|March 22, 2008

The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial, S M Bentzen, R K Agrawal, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 24, 2022

Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancerN C Turner, C Swift, B Jenkins, et al.

Lancet (London, England)|February 20, 2007

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialR C Coombes, L S Kilburn, C F Snowdon, et al.

Pageof 7